Storage of expensive anticancer drugs
Rosenthal, R.C.; Michalski, D.
Journal of the American Veterinary Medical Association 198(1): 144-146
1991
ISSN/ISBN: 0003-1488 PMID: 1995573 Document Number: 376800
Document emailed within 1 workday
Related Documents
2015: New drugs and indications in 2014. Some advances this year, but many drugs are poorly evaluated, too expensive, or more dangerous than useful Prescrire International 24(159): 107-110Huff, C. 2018: MS Drugs: Expensive, Often Lifelong, and not Cost Effective Managed Care 27(10): 30-34
Tax, S.E.M.; van der Hoeven, J.J.M.K. 2014: Expensive new drugs for treating cancer: a dilemma Nederlands Tijdschrift Voor Geneeskunde 158: A8034
Mileshkin, L.; Sullivan, D. 2011: Access to expensive anti-cancer drugs Journal of Law and Medicine 19(2): 232-243
Andersson, F.; Rydén-Bergsten, T. 1998: Heart failure is expensive! Correct drug utilization can reduce the number of of expensive days in hospital Lakartidningen 95(24): 2828-2830
Ben Aïssa, A.; George, A-C.; El M'Rabet, F.Z.; Mach, N.; Dietrich, P-Y.; Pechère-Bertschi, A. 2011: Anticancer drugs under pressure Revue Medicale Suisse 7(308): 1761-1766
Bénard, J.; Rixe, O. 1996: Resistance to anticancer drugs Presse Medicale 25(35): 1724-1730
Young, R.S. 1979: Problems of toxicity of anticancer drugs Federation Proceedings 38(1): 113-114
Fattoruso, S.I.S.; Di Lauro, L.; Conti, F.; Amodio, A.; Lopez, M. 2008: Target selectivity of anticancer drugs La Clinica Terapeutica 159(3): 189-206
Plunkett, W.; Gandhi, V. 1993: Cellular pharmacodynamics of anticancer drugs Seminars in Oncology 20(1): 50-63
Schmähl, D. 1986: Carcinogenicity of anticancer drugs and especially alkylating agents Iarc Scientific Publications 78: 29-35
Piuhola, J.; Tenhunen, O.; Kerkelä, R. 2015: Adverse cardiac effects associated with anticancer drugs Duodecim; Laaketieteellinen Aikakauskirja 131(5): 441-447
Ogawa, M. 1983: Current clinical status of new anticancer drugs Gan no Rinsho. Japan Journal of Cancer Clinics 29(10): 1049-1052
Tsukagoshi, S. 1993: Recent development of new anticancer drugs in Japan Nihon Rinsho. Japanese Journal of Clinical Medicine 51(7): 1923-1929
Collins, J.M. 1988: Improving the use of anticancer drugs: clinical pharmacokinetic approaches Israel Journal of Medical Sciences 24(9-10): 483-487
Gokhale, S.V.; Ganu, U.K.; Ambaye, R.Y. 1985: Effects of anticancer drugs on folate disposition and excretion Journal of Postgraduate Medicine 31(3): 123-127
Powis, G. 1994: Recent advances in the development of anticancer drugs that act against signalling pathways Tumori 80(2): 69-87
Baryshnikov, A.I. 2012: Nanostructured liposomal systems as transport agents for anticancer drugs Vestnik Rossiiskoi Akademii Meditsinskikh Nauk 3: 23-31
Gmeiner, W.H. 1998: NMR spectroscopy as a tool to investigate the structural basis of anticancer drugs Current Medicinal Chemistry 5(2): 115-135
Harguindey, S.; Arranz, J.L.; Wahl, M.L.; Orive, G.; Reshkin, S.J. 2009: Proton transport inhibitors as potentially selective anticancer drugs Anticancer Research 29(6): 2127-2136